These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
355 related articles for article (PubMed ID: 23956233)
1. Visual acuity of children treated with chemotherapy for optic pathway gliomas. Kalin-Hajdu E; Décarie JC; Marzouki M; Carret AS; Ospina LH Pediatr Blood Cancer; 2014 Feb; 61(2):223-7. PubMed ID: 23956233 [TBL] [Abstract][Full Text] [Related]
2. Visual outcome of a cohort of children with neurofibromatosis type 1 and optic pathway glioma followed by a pediatric neuro-oncology program. Dalla Via P; Opocher E; Pinello ML; Calderone M; Viscardi E; Clementi M; Battistella PA; Laverda AM; Da Dalt L; Perilongo G Neuro Oncol; 2007 Oct; 9(4):430-7. PubMed ID: 17704361 [TBL] [Abstract][Full Text] [Related]
3. Natural history and outcome of optic pathway gliomas in children. Nicolin G; Parkin P; Mabbott D; Hargrave D; Bartels U; Tabori U; Rutka J; Buncic JR; Bouffet E Pediatr Blood Cancer; 2009 Dec; 53(7):1231-7. PubMed ID: 19621457 [TBL] [Abstract][Full Text] [Related]
4. Neurofibromatosis type 1 and optic pathway gliomas: follow-up of 54 patients. Thiagalingam S; Flaherty M; Billson F; North K Ophthalmology; 2004 Mar; 111(3):568-77. PubMed ID: 15019338 [TBL] [Abstract][Full Text] [Related]
5. Optic pathway glioma: long-term visual outcome in children without neurofibromatosis type-1. Campagna M; Opocher E; Viscardi E; Calderone M; Severino SM; Cermakova I; Perilongo G Pediatr Blood Cancer; 2010 Dec; 55(6):1083-8. PubMed ID: 20979170 [TBL] [Abstract][Full Text] [Related]
6. Long-term visual outcomes of optic pathway gliomas in pediatric patients without neurofibromatosis type 1. Wan MJ; Ullrich NJ; Manley PE; Kieran MW; Goumnerova LC; Heidary G J Neurooncol; 2016 Aug; 129(1):173-8. PubMed ID: 27311725 [TBL] [Abstract][Full Text] [Related]
7. Visual outcomes in children with neurofibromatosis type 1-associated optic pathway glioma following chemotherapy: a multicenter retrospective analysis. Fisher MJ; Loguidice M; Gutmann DH; Listernick R; Ferner RE; Ullrich NJ; Packer RJ; Tabori U; Hoffman RO; Ardern-Holmes SL; Hummel TR; Hargrave DR; Bouffet E; Charrow J; Bilaniuk LT; Balcer LJ; Liu GT Neuro Oncol; 2012 Jun; 14(6):790-7. PubMed ID: 22474213 [TBL] [Abstract][Full Text] [Related]
8. Visual outcome following chemotherapy for progressive optic pathway gliomas. Shofty B; Ben-Sira L; Freedman S; Yalon M; Dvir R; Weintraub M; Toledano H; Constantini S; Kesler A Pediatr Blood Cancer; 2011 Sep; 57(3):481-5. PubMed ID: 21241008 [TBL] [Abstract][Full Text] [Related]
9. Feasibility and comparison of visual acuity testing methods in children with neurofibromatosis type 1 and/or optic pathway gliomas. Avery RA; Bouffet E; Packer RJ; Reginald A Invest Ophthalmol Vis Sci; 2013 Feb; 54(2):1034-8. PubMed ID: 23329671 [TBL] [Abstract][Full Text] [Related]
10. Long-term visual outcome after chemotherapy for optic pathway glioma in children: Site and age are strongly predictive. Dodgshun AJ; Elder JE; Hansford JR; Sullivan MJ Cancer; 2015 Dec; 121(23):4190-6. PubMed ID: 26280460 [TBL] [Abstract][Full Text] [Related]
11. Neurofibromatosis Type 1-Associated Optic Pathway Glioma in Children: A Follow-Up of 10 Years or More. Kinori M; Armarnik S; Listernick R; Charrow J; Zeid JL Am J Ophthalmol; 2021 Jan; 221():91-96. PubMed ID: 32283094 [TBL] [Abstract][Full Text] [Related]
12. Optic pathway gliomas in patients with neurofibromatosis type 1: follow-up of 44 patients. Segal L; Darvish-Zargar M; Dilenge ME; Ortenberg J; Polomeno RC J AAPOS; 2010 Apr; 14(2):155-8. PubMed ID: 20451859 [TBL] [Abstract][Full Text] [Related]
13. Longitudinal measures of visual function, tumor volume, and prediction of visual outcomes after treatment of optic pathway gliomas. Kelly JP; Leary S; Khanna P; Weiss AH Ophthalmology; 2012 Jun; 119(6):1231-7. PubMed ID: 22364864 [TBL] [Abstract][Full Text] [Related]
14. Visual outcomes after chemotherapy for optic pathway glioma in children with and without neurofibromatosis type 1: results of the International Society of Paediatric Oncology (SIOP) Low-Grade Glioma 2004 trial UK cohort. Falzon K; Drimtzias E; Picton S; Simmons I Br J Ophthalmol; 2018 Oct; 102(10):1367-1371. PubMed ID: 29343527 [TBL] [Abstract][Full Text] [Related]
16. Fractional anisotropy of the optic radiations is associated with visual acuity loss in optic pathway gliomas of neurofibromatosis type 1. de Blank PM; Berman JI; Liu GT; Roberts TP; Fisher MJ Neuro Oncol; 2013 Aug; 15(8):1088-95. PubMed ID: 23658320 [TBL] [Abstract][Full Text] [Related]
17. Screening and diagnosis of optic pathway gliomas in children with neurofibromatosis type 1 by using sweep visual evoked potentials. Chang BC; Mirabella G; Yagev R; Banh M; Mezer E; Parkin PC; Westall CA; Buncic JR Invest Ophthalmol Vis Sci; 2007 Jun; 48(6):2895-902. PubMed ID: 17525226 [TBL] [Abstract][Full Text] [Related]
18. Follow-up of optic pathway gliomas in children with neurofibromatosis type 1. Kuenzle C; Weissert M; Roulet E; Bode H; Schefer S; Huisman T; Landau K; Boltshauser E Neuropediatrics; 1994 Dec; 25(6):295-300. PubMed ID: 7770126 [TBL] [Abstract][Full Text] [Related]
19. A molecular analysis of individuals with neurofibromatosis type 1 (NF1) and optic pathway gliomas (OPGs), and an assessment of genotype-phenotype correlations. Sharif S; Upadhyaya M; Ferner R; Majounie E; Shenton A; Baser M; Thakker N; Evans DG J Med Genet; 2011 Apr; 48(4):256-60. PubMed ID: 21278392 [TBL] [Abstract][Full Text] [Related]
20. A novel mutation in the NF1 gene in two siblings with neurofibromatosis type 1 and bilateral optic pathway glioma. Kebudi R; Tuncer S; Upadhyaya M; Peksayar G; Spurlock G; Yazici H Pediatr Blood Cancer; 2008 Mar; 50(3):713-5. PubMed ID: 17514731 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]